Methylprednisolone added to clot removal for large stroke with low lymphocytes
Tests methylprednisolone with thrombectomy in adults with large acute ischemic strokes and low lymphocytes.
Plain-language title generated from the registry record
Registry title: Methylprednisolone for Stroke With Large Infarct Core and Post-stroke Lymphocytopenia
Key facts
- Where
- Fuzhou, ChinaSee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a sudden stroke from a blocked brain artery, a large area of damaged brain, and a low lymphocyte count, who will have a clot-removal procedure.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Stroke in the front part of the brain, with a blocked artery (internal carotid, or M1 or M2 part of the middle cerebral artery). Last known well within 24 hours. NIHSS score of at least 6. ASPECTS score below 6, or core infarct volume of at least 50 ml.
- Earlier treatment
- Planned treatment with endovascular thrombectomy (EVT), a procedure to remove the clot.
- Biomarker or test result
- Blood lymphocyte count below 0.8×10#/L at the start.
Main reasons for not taking part
- Bleeding inside the skull seen on CT or MRI
- mRS score above 2 before the stroke
- Pregnant or breastfeeding women
- Allergy to contrast agents or glucocorticoids
- Chronic hemodialysis or severe kidney problems
Read by machine on 12 November 2026.
Where in China
- Department of Neurology, the First Affiliated Hospital Fujian Medical UniversityFuzhou, ChinaContact: Yi Lin, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- YiLin
- Trial code
- NCT07202143
- Record updated
- 1 October 2025
- Original description
The efficacy and safety of early adjunctive methylprednisolone therapy in acute ischemic stroke patients with large infarct cores (ASPECTS score < 6) and post-stroke lymphocytopenia remain unclear. These immunocompromised patients face higher mortality rates and poorer clinical outcomes, with limited effective treatment options currently available. This multicenter, randomized, double-blind, placebo-controlled, non-inferiority trial aims to demonstrate that early methylprednisolone administration combined with reperfusion therapy is non-inferior to placebo in terms of survival and functional outcomes at 90 days.Read full original descriptionShow less
Methylprednisolone as Adjunct to Endovascular Thrombectomy for Acute Ischemic Stroke With Large Infarct Core and Post-stroke Lymphocytopenia -A Multicenter, Randomized, Double-blind, Placebo-controlled, Non-inferiority Trial
The efficacy and safety of early adjunctive methylprednisolone therapy in acute ischemic stroke patients with large infarct cores (ASPECTS score < 6) and post-stroke lymphocytopenia remain unclear. These immunocompromised patients face higher mortality rates and poorer clinical outcomes, with limited effective treatment options currently available. This multicenter, randomized, double-blind, placebo-controlled, non-inferiority trial aims to demonstrate that early methylprednisolone administration combined with reperfusion therapy is non-inferior to placebo in terms of survival and functional outcomes at 90 days.
Inclusion: Age ≥ 18 years; The time from last known well to randomization was within 24 hours; Anterior circulation ischemic stroke was preliminarily determined according to clinical symptoms or imaging examination; Occlusion of the intracranial internal carotid artery, the M1- or M2-segment of the middle cerebral artery by confirmed by CT angiography (CTA), MR angiography (MRA), or digital subtraction angiography (DSA); Baseline National Institutes of Health Stroke Scale (NIHSS) ≥ 6; Baseline Alberta Stroke Program Early CT Score (ASPECTS) < 6 (based on non-contrast CT or MRI) or core infarct volume ≥ 50 ml (based on CTP with rCBF < 30%); Planned treatment with endovascular thrombectomy (EVT); Baseline peripheral blood lymphocyte < 0.8×10#/L; Informed consent obtained from patients or their legal representatives.
Exclusion: Intracranial hemorrhage confirmed by cranial CT or MRI; Allergic to contrast agents or glucocorticoids; Bleeding history (gastrointestinal and urinary tract bleeding) in recent 1 month; Life expectancy due to any advanced disease < 6 months; Systemic infectious disease; Chronic hemodialysis and severe renal insufficiency (glomerular filtration rate < 30 ml/min or serum creatinine > 220 umol/L [2.5 mg/ dL]); mRS score > 2 before the time of last known well; Pregnant or lactating women; Participating in other clinical trials; The artery is tortuous so that the thrombectomy device cannot reach the target vessel; Follow-up is not expected to be completed; Intracranial aneurysm and arteriovenous malformation; Brain tumors with imaging mass effect.